Skip to main content

Advertisement

SpringerLink
Log in

Gliomatosis Cerebri Type 1 with Extensive Involvement of the Spinal Cord and BRAF V600E Mutation

  • Communication
  • Published:
Pathology & Oncology Research

Abstract

Gliomatosis cerebri (GC) is a rare neoplasm in which there is a diffuse cerebral infiltration by malignant glial cells with relative conservation of the underlying structures. A 67-year-old lady was admitted complaining of balance problems, troubled breathing, stuttered speech, decreased mobility, progressive ataxia and also some mild cognitive problems. MRI demonstrated ill defined T2 hyperintensity with mild mass effect mainly involving the brain stem and cerebellar hemispheres, with minor signal abnormalities extending supratentorially along the corticospinal tracts. The imaging appearances were static over a year. No biopsy was performed. The patient received palliative care and died 2 years after initial presentation. Macroscopic examination of the brain showed an extensive firm white-grey lesion predominantly in the cerebellar white matter, the brainstem, spreading to the full length of the spinal cord and invading the sensory ganglia. Histology revealed an extensively infiltrating diffuse glioma with small elongated fusiform nuclei. Diagnosis of GC type 1 was made. Molecular genetic tests revealed BRAF V600E mutation, while no IDH1 & IDH2 mutations were found. GC should be taken into account in the differential diagnoses mainly when there is rapid clinical deterioration without clear evidence of radiological progression. Extensive spinal cord infiltration has been reported only in 9 % and BRAF V600E mutation was detected only in one case in GC previously. Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Nevin S (1938) Gliomatosis cerebri. Brain 61:170–191

    Article  Google Scholar 

  2. Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76(2):201–205. doi:10.1007/s11060-005-5263-0

    Article  PubMed  Google Scholar 

  3. Herrlinger U, Felsberg J, Kuker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M (2002) Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 52(4):390–399. doi:10.1002/ana.10297

    Article  CAS  PubMed  Google Scholar 

  4. Thomas RP, Xu LW, Lober RM, Li G, Nagpal S (2013) The incidence and significance of multiple lesions in glioblastoma. J Neurooncol 112(1):91–97. doi:10.1007/s11060-012-1030-1

    Article  PubMed  Google Scholar 

  5. Lantos PLBJ (2000) Gliomatosis cerebri. In: Kleihues P, Cavence WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 92–93

    Google Scholar 

  6. Setty P, Hammes J, Rothamel T, Vladimirova V, Kramm CM, Pietsch T, Waha A (2010) A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn 12(6):750–756. doi:10.2353/jmoldx.2010.090237

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Song X, Andrew Allen R, Terence Dunn S, Fung KM, Farmer P, Gandhi S, Ranjan T, Demopoulos A, Symons M, Schulder M, Li JY (2011) Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 4(7):651–660

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Park S, Suh YL, Nam DH, Kim ST (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28(2):73–82

    Article  CAS  PubMed  Google Scholar 

  9. Troost D, Kuiper H, Valk J, Fleury P (1987) Gliomatosis cerebri, report of a clinically diagnosed and histologically confirmed case. Clin Neurol Neurosurg 89(1):43–47

    Article  CAS  PubMed  Google Scholar 

  10. LA Piccirilli M, Salvati M (2006) Gliomatosis cerebri treatment in 11 elderly patients. J Exp Clin Cancer Res 25(2):183–187

    CAS  PubMed  Google Scholar 

  11. Kim DG, Yang HJ, Park IA, Chi JG, Jung HW, Han DH, Choi KS, Cho BK (1998) Gliomatosis cerebri: clinical features, treatment, and prognosis. Acta Neurochirurgica 140(8):755–762. doi:10.1007/s007010050176

    Article  CAS  PubMed  Google Scholar 

  12. Kong DS, Kim ST, Lee JI, Suh YL, Lim do H, Kim WS, Kwon KH, Park K, Kim JH, Nam DH (2010) Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC Cancer 10:424. doi:10.1186/1471-2407-10-424

    Article  PubMed Central  PubMed  Google Scholar 

  13. Narasimhaiah D, Miquel C, Verhamme E, Desclee P, Cosnard G, Godfraind C (2012) IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology 32(1):30–37. doi:10.1111/j.1440-1789.2011.01216.x

    Article  PubMed  Google Scholar 

  14. Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G (1985) Gliomatosis cerebri: clinical and histological findings. Clin Neuropathol 4(4):135–148

    CAS  PubMed  Google Scholar 

  15. Corbett JJ, Newman NM (1981) Symptomatic leptomeningeal metastases preceding other manifestations of occult primary brain tumors. Surg Neurol 15(5):362–367

    Article  CAS  PubMed  Google Scholar 

  16. Karaca MAM, Hicsonmez A, Guney Y, Kurtman C (2006) Cases of glioblastoma multiforme metastasizing to spinal cord. Neurol India 54:428–430

    Article  PubMed  Google Scholar 

  17. Lawton CD, Nagasawa DT, Yang I, Fessler RG, Smith ZA (2012) Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease. J Neurosurg Spine 17(5):438–448. doi:10.3171/2012.7.SPINE12212

    Article  PubMed  Google Scholar 

  18. Balko MG, Blisard KS, Samaha FJ (1992) Oligodendroglial gliomatosis cerebri. Hum Pathol 23(6):706–707

    Article  CAS  PubMed  Google Scholar 

  19. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245–254. doi:10.1111/j.1750-3639.2009.00352.x

    Article  CAS  PubMed  Google Scholar 

  20. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C (2010) Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 120(2):261–267. doi:10.1007/s00401-010-0701-2

    Article  CAS  PubMed  Google Scholar 

  21. Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105(2):219–224. doi:10.1007/s11060-011-0587-4

    Article  CAS  PubMed  Google Scholar 

  22. Kwon MJ, Kim ST, Kong DS, Lee D, Park S, Kang SY, Song JY, Nam DH, Kato Y, Choi YL, Suh YL (2012) Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri. Brain Pathol 22(3):307–317. doi:10.1111/j.1750-3639.2011.00532.x

    Article  CAS  PubMed  Google Scholar 

  23. Mawrin C, Kirches E, Schneider-Stock R, Boltze C, Vorwerk CK, von Mawrin A, von Deimling A, Stoltenburg-Didinge G, Bornemann A, Romeike B, Sellhaus B, Dietzmann K (2005) Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol 72(2):115–122. doi:10.1007/s11060-004-2061-z

    Article  CAS  PubMed  Google Scholar 

  24. Liu W, Lv G, Li Y, Li L, Wang B (2011) Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. J Exp Clin Cancer Res 30:76. doi:10.1186/1756-9966-30-76

    Article  PubMed  Google Scholar 

  25. Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B, Faden AI (2005) Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A 102(23):8333–8338. doi:10.1073/pnas.0500989102

    Article  PubMed Central  PubMed  Google Scholar 

  26. Kouri FM, Jensen SA, Stegh AH (2012) The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. Sci World J 2012:838916. doi:10.1100/2012/838916

    Article  Google Scholar 

  27. Mawrin C, Lins H, Kirches E, Schildhaus HU, Scherlach C, Kanakis D, Dietzmann K (2003) Distribution of p53 alterations in a case of gliomatosis cerebri. Hum Pathol 34(1):102–106. doi:10.1053/hupa.2003.1

    Article  PubMed  Google Scholar 

  28. Wan PTGM, Roe SM, Lee S, NiculescuDuvaz D, Good VM, Jones CM, Marshall CJ, Springer CJBD, Marais R (2004) Cancer genome project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867. doi:10.1016/S0092-8674(04)00215-6

    Article  CAS  PubMed  Google Scholar 

  29. Capper D, Berghoff AS, von Deimling A, Preusser M (2012) Clinical neuropathology practice news 2-2012: BRAF V600E testing. Clin Neuropathol 31(2):64–66

    Article  PubMed  Google Scholar 

  30. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. doi:10.1007/s00401-011-0802-6

    Article  CAS  PubMed  Google Scholar 

  31. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37(5):685–698. doi:10.1097/PAS.0b013e31827f9c5e

    Article  PubMed  Google Scholar 

  32. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH (2012) Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A 109(22):8710–8715. doi:10.1073/pnas.1117255109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17(24):7595–7604. doi:10.1158/1078-0432.CCR-11-1456

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University Central Hospital of Asturias, Oviedo, Spain

    Ivan Fernandez-Vega

  2. Department of Neurology, Princess Royal University Hospital, Orpington, UK

    Jennifer Quirk & Fiona L. Norwood

  3. Department of Neurology, King’s College Hospital NHS Foundation Trust, London, UK

    Fiona L. Norwood

  4. Department of Neuroradiology, King’s College Hospital NHS Foundation Trust, London, UK

    Naomi A. Sibtain

  5. Department of Clinical Neuropathology, King’s College Hospital NHS Foundation Trust, London, UK

    Ross Laxton & Istvan Bodi

  6. Clinical Neuropathology, King’s College Hospital, Academic Neuroscience Building, Denmark Hill, London, SE5 9RS, UK

    Istvan Bodi

Authors
  1. Ivan Fernandez-Vega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Quirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fiona L. Norwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naomi A. Sibtain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ross Laxton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Istvan Bodi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Istvan Bodi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernandez-Vega, I., Quirk, J., Norwood, F.L. et al. Gliomatosis Cerebri Type 1 with Extensive Involvement of the Spinal Cord and BRAF V600E Mutation. Pathol. Oncol. Res. 20, 215–220 (2014). https://doi.org/10.1007/s12253-013-9732-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9732-z

Keywords

Search

Navigation